Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients
- PDF / 740,234 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 58 Downloads / 214 Views
NEPHROLOGY - ORIGINAL PAPER
Pentraxin‑3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients Baoxin Li1,2 · Xi Tian1,2 · Shuqin Guo1,2 · Mali Zhang1,2 · Jie Li1,2 · Na Zhai1,2 · He Wang1,2 · Yunliang Zhang1,2 Received: 16 March 2020 / Accepted: 7 July 2020 © Springer Nature B.V. 2020
Abstract Purpose Renal inflammatory response is involved in the development and progression of diabetic kidney disease (DKD). We sought to evaluate pentraxin-3 (PTX3) and adropin variability as inflammatory markers among type 2 diabetes mellitus (T2DM) patients with different urinary albumin, and to examine if these factors assist in the early diagnosis of diabetic kidney disease. Methods We enrolled 447 T2DM patients and 100 healthy non-diabetic control subjects in this study. The patients with T2DM were divided into three groups based on their urinary albumin/creatinine ratio (UACR): the normoalbuminuric group (DM group, UACR 300 mg/g). The levels of PTX3 and adropin were determined by enzyme-linked immunosorbent assay (ELISA). Spearman correlation and multiple linear regression analysis were performed to determine the correlations among these inflammatory markers and other clinical parameters. Receiver operating characteristic (ROC) curves analysis was used to assess the diagnostic potential of PTX3 and adropin for DKD. Results Compared to non-diabetes, serum levels of PTX3 were distinctly elevated, whereas the adropin were significantly declined in diabetic patients (p
Data Loading...
